J. C. Jennette, R. J. Falk, P. A. Bacon, N. Basu, M. C. Cid et al., , p.2012, 2013.

, Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis & Rheumatism, vol.65, pp.1-11

M. A. Gonzalez-gay, T. R. Vazquez-rodriguez, M. J. Lopez-diaz, J. A. Miranda-filloy, C. Gonzalez-juanatey et al., Epidemiology of giant cell arteritis and polymyalgia rheumatica, Arthritis & Rheumatism, issue.10, pp.1454-1461, 2009.

F. Buttgereit, C. Dejaco, E. L. Matteson, and B. Dasgupta, Polymyalgia rheumatica and giant cell arteritis a systematic review, JAMA -Journal of the American Medical Association, vol.315, issue.22, pp.2442-2458, 2016.

G. G. Hunder, R. Y. Leavitt, A. S. Fauci, D. A. Bloch, B. A. Michel et al.,

, The American College of Rheumatology 1990 Criteria for the classification of vasculitis Introduction, Arthritis & Rheumatism, vol.33, issue.8, pp.1065-1067

G. W. Smetana, Does This Patient Have Temporal Arteritis?, JAMA, vol.287, issue.1, 2002.

C. S. Crowson and E. L. Matteson, Contemporary Prevalence Estimates for Giant Cell Arteritis and Polymyalgia Rheumatica, Seminars in Arthritis and Rheumatism, vol.47, issue.2, pp.253-256, 2015.

,

E. Liozon, F. Dalmay, F. Lalloue, G. Gondran, H. Bezanahary et al., , 2016.

, Risk factors for permanent visual loss in biopsy-proven giant cell arteritis: A study of 339 patients, Journal of Rheumatology, vol.43, issue.7, pp.1393-1399

, Medicine, vol.111, issue.3, pp.770-777

G. Restuccia, L. Boiardi, A. Cavazza, M. Catanoso, P. Macchioni et al.,

, Long-term remission in biopsy proven giant cell arteritis: A retrospective cohort study, Journal of Autoimmunity, vol.77, pp.39-44

L. Sailler, G. Pugnet, and B. Bienvenu, Traitement de la maladie de Horton. La Revue de Médecine Interne, vol.34, pp.431-437, 2013.

C. Salvarani, F. Cantini, L. Boiardi, and G. G. Hunder, Polymyalgia rheumatica and giant cell arteritis, N Engl J Med, vol.347, issue.4, pp.261-271, 2002.

M. Samson and B. Bonnotte, De la physiopathologie de l'artérite à cellules géantes aux nouvelles cibles thérapeutiques, Revue de Medecine Interne, vol.38, issue.10, pp.670-678, 2017.

,

M. Mazlumzadeh, G. G. Hunder, K. A. Easley, K. T. Calamia, E. L. Matteson et al., Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: A double-blind, placebo-controlled, randomized prospective clinical trial, Arthritis and Rheumatism, vol.54, issue.10, pp.3310-3318, 2006.

J. A. Fraser, C. M. Weyand, N. J. Newman, and V. Biousse, The Treatment of Giant Cell Arteritis, GEFA). Revue de Medecine Interne, vol.5, issue.3, pp.154-165, 2008.

,

A. Mahr, C. Agard, M. André, B. Bienvenu, M. Lambert et al., Protocole National de Diagnostic et de Soins PNDS Artérite à Cellules Géantes (Horton), 2017.

A. Proven, S. E. Gabriel, C. Orces, W. M. O'fallon, and G. G. Hunder, Glucocorticoid therapy in giant cell arteritis: Duration and adverse outcomes, Arthritis & Rheumatism, vol.49, issue.5, pp.703-708, 2003.

,

J. C. Wilson, K. Sarsour, N. Collinson, K. Tuckwell, D. Musselman et al., , 2016.

, Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis, Seminars in Arthritis and Rheumatism, vol.0, issue.0, pp.436-442

,

A. R. Behn, T. Perera, and A. B. Myles, Polymyalgia rheumatica and corticosteroids: How much for how long?, Annals of the Rheumatic Diseases, vol.42, issue.4, pp.374-378, 1983.

,

R. Andersson, B. Malmwall, and B. Bengtsson, Long-term Corticosteroid Treatment in Giant Cell Arteritis, Acta Medica Scandinavica, vol.220, issue.5, pp.465-469, 1986.

F. Buttgereit, E. L. Matteson, C. Dejaco, and B. Dasgupta, Prevention of glucocorticoid morbidity in giant cell arteritis, Rheumatology (United Kingdom), vol.57, pp.11-21, 2018.

,

V. Kyle and B. L. Hazleman, Treatment of polymyalgia rheumatica and giant cell arteritis. I, 1989.

, Steroid regimens in the first two months, Annals of the Rheumatic Diseases, vol.48, issue.8, pp.658-661

,

M. S. Broder, K. Sarsour, E. Chang, N. Collinson, K. Tuckwell et al., Corticosteroid-related adverse events in patients with giant cell arteritis: A claims-based analysis, Seminars in Arthritis and Rheumatism, vol.46, issue.2, pp.246-252, 2016.

,

A. Caplan, N. Fett, M. Rosenbach, V. P. Werth, and R. G. Micheletti, Prevention and management of glucocorticoid-induced side effects : A comprehensive review, Journal of American Dermatology, vol.76, issue.2, pp.201-207, 2017.

P. C. Souverein, Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular, 2004.

J. T. Myklebust and G. Gran, Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis-A prospective two-year study in 273 patients, Scand J Rheumatol, vol.30, pp.260-267, 2001.

P. Protocole and . Eudract, , pp.2008-004896

J. H. Stone, K. Tuckwell, S. Dimonaco, M. Klearman, M. Aringer et al., Trial of Tocilizumab in Giant-Cell Arteritis, New England Journal of Medicine, vol.377, issue.4, pp.317-328, 2017.

G. S. Hoffman, M. C. Cid, D. B. Hellmann, L. Guillevin, J. H. Stone et al., A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis, Arthritis and Rheumatism, vol.46, issue.5, pp.1309-1318, 2002.

,

G. G. Hunder, S. G. Sheps, A. Gl, and J. W. Joyce, Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study, Ann Intern Med, vol.82, issue.5, pp.613-618, 1975.

C. Mukhtyar, L. Guillevin, M. C. Cid, B. Dasgupta, K. De-groot et al., , 2009.

, EULAR recommendations for the management of large vessel vasculitis, Annals of the Rheumatic Diseases, vol.68, issue.3, pp.318-323

M. A. Alba, A. García-martínez, S. Prieto-gonzález, I. Tavera-bahillo, M. Corbera-bellalta et al., Relapses in Patients With Giant Cell Arteritis, Medicine, vol.93, issue.5, pp.194-201, 2014.

L. Martinez-lado, C. Calviño-díaz, A. Piñeiro, T. Dierssen, T. R. Vazquez-rodriguez et al., Relapses and Recurrences in Giant Cell Arteritis, Medicine, vol.90, issue.3, pp.186-193, 2011.

T. A. Kermani, K. J. Warrington, D. Cuthbertson, S. Carette, G. S. Hoffman et al.,

S. R. Ytterberg, Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study, The Journal of Rheumatology, vol.42, issue.7, pp.1213-1217, 2015.

,

G. Restuccia, L. Boiardi, A. Cavazza, M. Catanoso, P. Macchioni et al., Flares in Biopsy-Proven Giant Cell Arteritis in Northern Italy, Medicine, vol.95, issue.19, 2016.

C. Labarca, M. J. Koster, C. S. Crowson, A. Makol, S. R. Ytterberg et al.,

K. J. , Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: A retrospective cohort study, Rheumatology (United Kingdom), vol.55, issue.2, pp.347-356, 2015.

,

J. Hernández-rodríguez, A. García-martínez, J. Casademont, X. Filella, M. Esteban et al., A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant, 2002.

, Arthritis & Rheumatism, vol.47, issue.1, pp.29-35

H. De-boysson, E. Liozon, M. Lambert, A. Dumont, J. Boutemy et al., , 2017.

G. Arteritis, Do We Treat Patients with Large-Vessel Involvement Differently?, The American Journal of Medicine, vol.130, issue.8, pp.992-995